Highwire performed the Management Due Diligence on MAP, a Life Sciences company, which is a dedicated to accelerating patient access to ground-breaking medicines, devices, and diagnostics. It has a proven track record of helping its customers navigate increasingly complex healthcare reimbursement pathways, with particular expertise in rare and orphan diseases and cell and gene therapies.
The investment will enable the strong management team to accelerate growth by broadening its service offering and expanding into new territories.
“Highwire’s assessment of the management team was a key part of our due diligence and provided us with valuable insights into both the key individuals and broader team culture at MAP. We wouldn’t hesitate in recommending Sandra and Alton and the Highwire team.”
Kester Capital team led by Peter Ralph, Ben Woolley and Jack Murphy